Kazia Therapeutics Limited American Depositary Shares
KZIA$10.87 +0.52 (5.21%)
Company News
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
Kazia Therapeutics reported a patient with stage IV triple-negative breast cancer achieved an initial immune-complete response when treated with paxalisib combined with pembrolizumab and standard chemotherapy, showing a profound radiologic response in a highly aggressive cancer subtype.
Leptomeningeal Metastases Market to Exhibit Growth at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) | DelveInsight
The leptomeningeal metastases market is projected to grow slowly due to rising cancer incidence and increasing central nervous system complications. Several emerging therapies like REYOBIQ and Paxalisib are expected to drive market development in the coming years.
Beat the Market the Zacks Way: Kazia Therapeutics, Uber, Medtronic in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
